Arca
Skip to content
Tools
Tools

Melanoma cell

Cell-line in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Other 1

Approved1

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        Talimogene laherparepvecApprovedAmgenGeneDisrupting agentMelanoma cell disrupting agent9

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Talimogene laherparepvecPhase 1RecruitingJohns Hopkins UniversityAug 3, 2025
        Neoadjuvant Intralesional Injection of Talimogene LaherparepvecTalimogene laherparepvecPhase 2Active, not recruitingJohn RiethOct 28, 2024
        TVEC and Preop Radiation for Sarcoma (8 ml Dose)Talimogene laherparepvecPhase 1 / Phase 2Active, not recruitingJohn RiethOct 22, 2020
        Talimogene Laherparepvec, Nivolumab and Trabectedin for SarcomaTalimogene laherparepvecPhase 2RecruitingSarcoma Oncology Research Center, LLCMar 22, 2019
        Neoadjuvant Combination Immunotherapy for Stage III MelanomaTalimogene laherparepvecPhase 2RecruitingUniversity of LouisvilleFeb 15, 2019
        A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaTalimogene laherparepvecPhase 2Active, not recruitingMemorial Sloan Kettering Cancer CenterMar 3, 2017
        Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersTalimogene laherparepvecPhase 2Active, not recruitingNational Cancer Institute (NCI)Dec 1, 2016
        Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTalimogene laherparepvecPhase 2Active, not recruitingNational Cancer Institute (NCI)Nov 17, 2016

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL614126, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.